Antifungal lock therapy with combined 70% ethanol and micafungin in a critically ill infant

Fiammetta Piersigilli1, Cinzia Auriti, Iliana Bersani

  • 1From the *Department of Neonatology; †Department of Biochemical and Clinical Laboratory; and ‡Pharmacy Unit, Bambino Gesù Children's Hospital, Rome, Italy.

Insights

Ethanol lock therapy combined with systemic antifungals successfully treated candidemia in an infant, avoiding central venous catheter removal. This approach offers a potential alternative for managing catheter-related fungal infections in neonates.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Central venous catheters are essential for neonatal care but pose infection risks.
  • Catheter-related candidemia is a serious complication in neonates, often requiring catheter removal.
  • Lock therapy, using antimicrobial solutions in the catheter lumen, is explored to preserve catheters during infection.

Observation:

  • A neonate developed catheter-related candidemia despite systemic antifungal treatment.
  • Standard systemic therapy failed to clear the fungal bloodstream infection.
  • The patient required an alternative treatment strategy to resolve the infection.

Findings:

  • Combined therapy of ethanol 70% lock solution and micafungin sodium was administered.
  • Blood cultures became sterile after the introduction of lock therapy.
  • Successful eradication of candidemia was achieved while maintaining catheter patency.

Implications:

  • Ethanol lock therapy may be a viable option for treating neonatal candidemia, potentially avoiding catheter removal.
  • This approach could reduce treatment costs and complications associated with catheter replacement.
  • Further research is warranted to establish optimal protocols and efficacy in larger neonatal populations.